Results
As of December 2021, among 448 eligible DFCI 16-001 participants, 392
(87.5%) opted-in to the SDoH study (Figure 1), of whom 375 (95.7%)
completed T0 surveys a median of 19 days (range, 1-35 days) from trial
registration. Longitudinal response rates were 90.9% (T1), 92.8% (T2),
and 87.2% (T3). Complete HMH data (98.2-99.3%, T0-T3) and complete
income data (89.6%-91.6%, T0-T3) were provided in nearly all surveys.
Patient and leukemia characteristics did not differ between SDoH study
participants and non-participants (Table 1).